AstraZeneca PLC(AZN)NASDAQ
Stock Performance & Returns
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
AZN | 255.54 B | 24.63x | 6.40% | 17.02% | $6.69 | 21.97% | 0.64 | 1.96% | $210.52 | $144.30 |
AZN.L | 18.84 T | 2473.73x | 6.40% | 17.02% | $4.91 | 21.97% | 0.64 | 2.00% | $15729.35 | $9891.35 |
HLN.L | 3.15 T | 1986.67x | 2.20% | 14.55% | $0.18 | 10.09% | 0.50 | 1.98% | $416.02 | $274.35 |
HIK.L | 332.18 B | 1234.62x | 4.20% | 11.32% | $1.30 | 15.41% | 0.77 | 3.93% | $1864.06 | $1186.40 |
Peer Valuation & Performance Analysis
Peer group analysis for AstraZeneca PLC (AZN) compared to its primary competitors (including AZN.L, HLN.L, HIK.L) reveals distinct metrics. AZN trades at a valuation discount relative to its competitors, with a P/E ratio of 24.6x versus the peer average of 1898.3x (representing a 99% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, AZN's revenue growth of 6.4% exceeds the peer average of 4.3%, highlighting its competitive strength and market share gains. Additionally, it boasts superior profitability with a net margin of 17.0% compared to the peer average of 14.3%, demonstrating strong cost controls and pricing power.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• AZN ranks #1 in P/E ratio, #1 in revenue growth, and #1 in profit margins
• Average ranking: #1 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-09-03 | $165.64 | $165.74 | $162.24 | $164.77 | 2,425,200 | -0.53% |
| 2026-09-02 | $162.54 | $164.69 | $160.87 | $161.63 | 3,300,800 | -0.56% |
| 2026-09-01 | $163.66 | $164.24 | $161.39 | $162.47 | 2,598,500 | -0.73% |
| 2026-08-31 | $162.70 | $163.75 | $161.95 | $162.13 | 3,067,800 | -0.35% |
| 2026-08-28 | $163.52 | $163.54 | $161.18 | $162.70 | 2,880,700 | -0.50% |
| 2026-08-27 | $165.27 | $165.58 | $163.98 | $164.52 | 2,495,200 | -0.45% |
| 2026-08-26 | $167.46 | $167.89 | $165.17 | $166.27 | 2,680,600 | -0.71% |
| 2026-08-25 | $167.08 | $170.18 | $166.78 | $169.66 | 3,453,200 | +1.54% |
| 2026-08-24 | $164.57 | $167.08 | $163.97 | $166.71 | 2,780,100 | +1.30% |
| 2026-08-21 | $164.04 | $167.25 | $163.96 | $165.98 | 3,179,600 | +1.18% |
| 2026-08-20 | $163.40 | $165.57 | $161.48 | $164.49 | 5,094,000 | +0.67% |
| 2026-08-19 | $162.13 | $165.91 | $162.00 | $164.95 | 3,817,200 | +1.74% |
| 2026-08-18 | $159.12 | $160.64 | $158.98 | $160.10 | 3,001,300 | +0.62% |
| 2026-08-17 | $156.30 | $157.26 | $155.78 | $156.89 | 3,361,600 | +0.38% |
| 2026-08-14 | $155.50 | $156.46 | $154.53 | $156.45 | 3,697,500 | +0.61% |
Explore More Analysis for AZN
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.